Boston, MA -- (SBWIRE) -- 10/01/2013 -- The Musculoskeletal Symptoms Partnering 2007-2013 report provides understanding and access to the musculoskeletal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in musculoskeletal symptoms partnering deals
- Top musculoskeletal symptoms deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type

The Musculoskeletal Symptoms Partnering 2007-2013 provides understanding and access to the musculoskeletal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

View Full Report Details and Table of Contents

The report provides an analysis of musculoskeletal symptoms partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors asthma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains over 20 links to online copies of actual musculoskeletal symptoms deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of musculoskeletal symptoms partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in musculoskeletal symptoms partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading musculoskeletal symptoms deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Musculoskeletal Pain Global Clinical Trials Review, H1, 2013
- Musculoskeletal Transplant Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Other Musculoskeletal Disorders - Pipeline Review, H2 2012
- Vasomotor Symptoms of Menopause - Pipeline Review, H2 2012
- Musculoskeletal Pain - Pipeline Review, H1 2013
- Vasomotor Symptoms of Menopause - Pipeline Review, H1 2013
- MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022
- Musculoskeletal Transplant Foundation - Medical Equipment - Deals and Alliances Profile
- Treatment Algorithms: Postherpetic Neuralgia - Lyrica forms the cornerstone of treatment for postherpetic neuralgia
- PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022